SANOFI-AVENTIS [FR0000120578 / SAN]

FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease

INFORMATION REGLEMENTEE
Download the original document | View the text document

[11/12/2013 | 07:00]



Read all communications published by SANOFI-AVENTIS
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2020 SYMEX ECONOMICS all rights reserved